Natural Products Impacting DNA Methyltransferases and Histone Deacetylases.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Akone, Sergi HerveNtie-Kang, Fidele
Stuhldreier, Fabian
Ewonkem, Monique Bassomo
Noah, Alexandre Mboene
Mouelle, Simon Eitel Misse
Müller, Rolf
Issue Date
2020-08-13
Metadata
Show full item recordAbstract
Epigenetics refers to heritable changes in gene expression and chromatin structure without change in a DNA sequence. Several epigenetic modifications and respective regulators have been reported. These include DNA methylation, chromatin remodeling, histone post-translational modifications, and non-coding RNAs. Emerging evidence has revealed that epigenetic dysregulations are involved in a wide range of diseases including cancers. Therefore, the reversible nature of epigenetic modifications concerning activation or inhibition of enzymes involved could be promising targets and useful tools for the elucidation of cellular and biological phenomena. In this review, emphasis is laid on natural products that inhibit DNA methyltransferases (DNMTs) and histone deacetylases (HDACs) making them promising candidates for the development of lead structures for anticancer-drugs targeting epigenetic modifications. However, most of the natural products targeting HDAC and/or DNMT lack isoform selectivity, which is important for determining their potential use as therapeutic agents. Nevertheless, the structures presented in this review offer the well-founded basis that screening and chemical modifications of natural products will in future provide not only leads to the identification of more specific inhibitors with fewer side effects, but also important features for the elucidation of HDAC and DNMT function with respect to cancer treatment.Citation
Front Pharmacol. 2020 Aug 13;11:992. doi: 10.3389/fphar.2020.00992. PMID: 32903500; PMCID: PMC7438611.Affiliation
HIPS, Helmholtz-Institut für Pharmazeutische Forschung Saarland, Universitätscampus E8.1 66123 Saarbrücken, Germany.Publisher
FrontiersJournal
Frontiers in pharmacologyPubMed ID
32903500Type
ReviewOther
Language
enISSN
1663-9812ae974a485f413a2113503eed53cd6c53
10.3389/fphar.2020.00992
Scopus Count
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
Related articles
- Treatment of cardiovascular pathology with epigenetically active agents: Focus on natural and synthetic inhibitors of DNA methylation and histone deacetylation.
- Authors: Chistiakov DA, Orekhov AN, Bobryshev YV
- Issue date: 2017 Jan 15
- Genistein Induces Alterations of Epigenetic Modulatory Signatures in Human Cervical Cancer Cells.
- Authors: Sundaram MK, Ansari MZ, Al Mutery A, Ashraf M, Nasab R, Rai S, Rais N, Hussain A
- Issue date: 2018
- An Update of Epigenetic Drugs for the Treatment of Cancers and Brain Diseases: A Comprehensive Review.
- Authors: Sahafnejad Z, Ramazi S, Allahverdi A
- Issue date: 2023 Apr 6
- Epigenetic control using natural products and synthetic molecules.
- Authors: Suzuki T, Miyata N
- Issue date: 2006
- Epigenetic therapy in non-small-cell lung cancer: targeting DNA methyltransferases and histone deacetylases.
- Authors: Vendetti FP, Rudin CM
- Issue date: 2013 Sep